Advertisement

Endogenous Opioids and Central Cardiovascular Control

  • A. I. Faden
  • T. K. Mcintosh
Part of the Topics in the Neurosciences book series (TNSC, volume 4)

Abstract

A number of endogenous opioid peptides have been identified since the discovery of the pentapeptide enkephalins in 1975. Like exogenous opiates, these substances have potent cardiovascular effects following administration into the central nervous system (CNS). Combined with the observation that endogenous opioids are concentrated in central cardioregulatory sites, such findings have suggested a role for these substances in central cardiovascular regulation. Findings from work in experimental shock and hypertension lend further support for this concept. This review summarizes the recent experimental evidence to support the conclusion that endogenous opioid systems may be important in central cardiovascular control.

Keywords

Nucleus Tractus Solitarius Endogenous Opioid Opiate Receptor Cardiovascular Action Endogenous Opioid Peptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bloom, F.E. Annu. Rev. Pharmacol. Toxicol. 23: 151–170, 1985.CrossRefGoogle Scholar
  2. 2.
    Faden, A.I. JAOA 84(Suppl 1): 129–134, 1984.PubMedGoogle Scholar
  3. 3.
    Frederickson, R.C., Geary, L.E. Prog. Neurobiol. 19: 19–69, 1982.PubMedCrossRefGoogle Scholar
  4. 4.
    Henry, J.L. Neurosci. Biobehav. Rev. 6: 229–245, 1982.PubMedCrossRefGoogle Scholar
  5. 5.
    Holaday, J.W. Annu. Rev. Pharmacol. Toxicol. 23: 541–594, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    Faden, A.I. JAMA 252: 1177–1180, 1984.PubMedCrossRefGoogle Scholar
  7. 7.
    Cox, B.M. Life Sci. 31: 1645–1658, 1982.PubMedCrossRefGoogle Scholar
  8. 8.
    Hassen, A.H., Feuerstein, G., Faden, A.I. J. Neurosci. 4: 2213–2221, 1984.PubMedGoogle Scholar
  9. 9.
    Holaday, J.W., Pasternak, G.W., Faden, A.I. Neurosci. Lett. 37: 199–204, 1983.PubMedCrossRefGoogle Scholar
  10. 10.
    Wuster, M., Schulz, R., Herz, A. Biochem. Pharmacol. 30: 1983, 1981.CrossRefGoogle Scholar
  11. 11.
    Delia Bella, D., Casacci, F., Sassi, A. Adv. Biochem. Phsycho-pharmacol. 18: 271–277, 1978.Google Scholar
  12. 12.
    Dupont, A., Lepine, J., Langelier, P., Merand, Y., Rouleau, D., Vaudry, H., Gros, C., Barden, N. Reg. Peptides 1: 43–52, 1980.CrossRefGoogle Scholar
  13. 13.
    Elde, R., Hokfelt, T., Johansson, O., Terenius, L. Neuroscience 1 349–351, 1976.PubMedCrossRefGoogle Scholar
  14. 14.
    Feuerstein, G., Molineaux, C.J., Rosenberger, J.G., Faden, A.I., Cox, B.M. Peptides 4: 225–229, 1983.PubMedCrossRefGoogle Scholar
  15. 15.
    Hokfelt, T., Elde, R., Johansson, O., Terenius, L., Stein, L. Neurosci. Lett. 5: 25–31, 1977.PubMedCrossRefGoogle Scholar
  16. 16.
    Hughes, J., Kosterlitz, H.W., Smith, T.W. Br. J. Pharmacol. 61: 639–648, 1977.PubMedGoogle Scholar
  17. 17.
    Khachaturian, H., Watson, S.J., Lewis, M.E., Coy, D., Goldstein, A. Akil, H. Peptides 3: 941–945, 1982.PubMedCrossRefGoogle Scholar
  18. 18.
    Pfeiffer, A., Herz, A. Molec. Pharmacol 21: 266–271, 1982.Google Scholar
  19. 19.
    Simantov, R., Kuhar, M.J., Uhl, G.R., Snyder, S.H. Proc. natn. Acad. Sci. USA 74: 2167–2172, 1977.CrossRefGoogle Scholar
  20. 20.
    Laubie, M., Schmitt, H., Vincent, M., Remond, G. Eur. J. Pharmacol. 46: 67–71, 1977.PubMedCrossRefGoogle Scholar
  21. 21.
    Bellet, M., Elghozi, J.L., Meyer, P., Pernollet, M.G., Schmitt, H. Br. J. Pharmacol. 71: 365–369, 1980.PubMedGoogle Scholar
  22. 22.
    Hassen, A.H., Feuerstein, G., Pfeiffer, A., Faden, A.I. Reg. Peptides 4: 299–309, 1982.CrossRefGoogle Scholar
  23. 23.
    Hassen, A.H., Feuerstein, G., Faden, A.I. Peptides 3: 1031–1037, 1982.PubMedCrossRefGoogle Scholar
  24. 24.
    Hassen, A.H., Feuerstein, G., Faden, A.I. Neuropharmacology 23: 407–415, 1984.PubMedCrossRefGoogle Scholar
  25. 25.
    Laubie, M., Schmitt, H., Vincent, M. Eur. J. Pharmacol. 59: 287–291, 1979.PubMedCrossRefGoogle Scholar
  26. 26.
    Holaday, J.W. Peptides 3: 1023–1029, 1982.PubMedCrossRefGoogle Scholar
  27. 27.
    Feldberg, W., Wei, E. J. Physiol. 275: 18P, 1978.Google Scholar
  28. 28.
    Feuerstein, G., Faden, A.I. Life Sci. 31: 2197–2200, 1982.PubMedCrossRefGoogle Scholar
  29. 29.
    Yukimura, T., Unger, T., Rascher, W., Lang, R.E., Ganten, D. Clin. Sci. 61: 347s-350s, 1981.Google Scholar
  30. 30.
    Wong, T.M., Chan, S.H.H., Tse, S.Y.H. Neurosci. Lett. 46: 249–254, 1984.PubMedCrossRefGoogle Scholar
  31. 31.
    Pfeiffer, A., Feuerstein, G., Kopin, I.J., Faden, A.I. J. Pharmac. exp. Ther. 225: 735–741, 1983.Google Scholar
  32. 32.
    Pfeiffer, A., Feuerstein, G., Zerbe, R.L., Faden, A.I., Kopin, I.J. Endocrinology 113: 929–938, 1983.PubMedCrossRefGoogle Scholar
  33. 33.
    Faden, A.I., Feuerstein, G. Br. J. Pharmacol. 79: 997–1002, 1983.PubMedGoogle Scholar
  34. 34.
    Arndt, J.O., Freye, E. Nature 277: 399–400, 1979.PubMedCrossRefGoogle Scholar
  35. 35.
    Berkowitz, B.A., Ngai, S.H., Finch, A.D. Science 194: 967–968, 1976.PubMedCrossRefGoogle Scholar
  36. 36.
    Florez, J., Mediavilla, A. Brain Res. 138: 585–590, 1977.PubMedCrossRefGoogle Scholar
  37. 37.
    Hassen, A.H., Feuerstein, G., Faden, A.I. Peptides 4: 621–625, 1983.PubMedCrossRefGoogle Scholar
  38. 38.
    Bolme, P., Fuxe, K., Agnati, L.F., Bradley, R., Smythies, J. Eur. J. Pharmacol. 48: 319–324, 1978.PubMedCrossRefGoogle Scholar
  39. 39.
    McDonald, W.J., Motter, M., Ganten, D., Lang, R.E. Clin. exp. Hypertens. 10: 1837–1841, 1984.CrossRefGoogle Scholar
  40. 40.
    Petty, M.A., De Jong, W. Eur. J. Pharmacol. 81: 449–457, 1982.PubMedCrossRefGoogle Scholar
  41. 41.
    Petty, M.A., Reid, J.L. Naunyn-Schmiedebergs exp. Path. Arch. Pharmak. 319: 206–211, 1982.CrossRefGoogle Scholar
  42. 42.
    Holaday, J.W., Faden, A.I. Nature 275: 450–451, 1978.PubMedCrossRefGoogle Scholar
  43. 43.
    Pfeiffer, A., Pfeiffer, D.G., Feuerstein, G., Faden, A.I., Kopin, I.J. Brain Res. 296: 305–311, 1984.PubMedCrossRefGoogle Scholar
  44. 44.
    Faden, A.I., Holaday, J.W. J. Pharmac. exp. Ther. 212: 441–447, 1980.Google Scholar
  45. 45.
    Faden, A.I., Holaday, J.W. Science 205: 317–318, 1979.PubMedCrossRefGoogle Scholar
  46. 46.
    Faden, A.I., Jacobs, T.P., Holaday, J.W. J. Auton. Nerv. Syst. 2: 295–304, 1980.PubMedCrossRefGoogle Scholar
  47. 47.
    Holaday, J.W., Faden, A.I. Brain Res. 189: 295–299, 1980.PubMedCrossRefGoogle Scholar
  48. 48.
    Janssen, H.F., Lutherer, L.O. Brain Res. 194: 608–612, 1980.PubMedCrossRefGoogle Scholar
  49. 49.
    Amir, S. Eur. J. Pharmacol. 80: 161–162, 1982.PubMedCrossRefGoogle Scholar
  50. 50.
    Feuerstein, G., Faden, A.I., Krumins, S.A. Eur. J. Pharmacol. 100: 245–246, 1984.PubMedCrossRefGoogle Scholar
  51. 51.
    Feuerstein, G., Molineaux, C.J., Rosenberger, J.G., Zerbe, R.L., Cox, B.M., Faden, A.I. Am. J. Physiol. 249: E244–E250, 1985.PubMedGoogle Scholar
  52. 52.
    Feuerstein, G., Powell, E., Faden, A.I. Peptides 6 (Suppl 1): 11–13, 1985.PubMedCrossRefGoogle Scholar
  53. 53.
    Zamir, N., Simantov, R., Segal, M. Brain Res. 184: 299–310, 1980.PubMedCrossRefGoogle Scholar
  54. 54.
    Wendel, O.T., Bennett, B. Life Sci. 29: 515–521, 1981.PubMedCrossRefGoogle Scholar
  55. 55.
    Schaz, K., Stock, G., Simon, W., Schlor, K.H., Unger, T., Rockhold, R. Ganten, D. Hypertension 2: 395–407, 1980.PubMedGoogle Scholar
  56. 56.
    Feuerstein, G., Zerbe, R.L., Faden, A.I. Hypertension 5: 663–671, 1983.PubMedGoogle Scholar
  57. 57.
    Farsang, C., Ramirez-Gonzalez, M.D., Mucci, L., Kunos, G. J. Pharmac. exp. Ther. 214: 203–208, 1980.Google Scholar
  58. 58.
    Holaday, J.W., D’Amato, R.J., Ruvio, B.A., Feuerstein, G., Faden, A.I. Circ. Shock 11: 201–210, 1983.PubMedGoogle Scholar
  59. 59.
    Van Loon, G.R., Appel, N.M., Ho, D. Brain Res. 212: 207–214, 1981.PubMedCrossRefGoogle Scholar
  60. 60.
    Simon, W., Schaz, K., Ganten, U., Stock, G., Schlor, K.H., Ganten, D. Clin. Sci. mol. Med. 55: 237s–241s, 1978.Google Scholar
  61. 61.
    Laubie, M., Schmitt, H. Eur. J. Pharmacol. 71: 401–409, 1981.PubMedCrossRefGoogle Scholar
  62. 62.
    Freye, E., Hartung, E., Schenk, G.K. Pharmacology 25: 6–11, 1982.PubMedCrossRefGoogle Scholar
  63. 63.
    Feuerstein, G., Faden, A.I. Neuropeptides 5: 295–298, 1984.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing 1986

Authors and Affiliations

  • A. I. Faden
    • 1
  • T. K. Mcintosh
    • 1
  1. 1.Department of NeurologyUniversity of California at San Francisco, and Neurology Service, San Francisco Veterans Administration Medical CenterSan FranciscoUSA

Personalised recommendations